Form 4: Opus Genetics Officer Sells Shares for Tax Obligations

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba Rabourn, sold 2,816 shares of common stock to cover tax withholding obligations from a restricted stock unit award.

Summary

• Amy Zaremba Rabourn, Head of Financial Quality Assurance at Opus Genetics, Inc. (IRD), reported a sale of common stock.
• On March 16, 2026, 2,816 shares of common stock were sold at a price of $5.245 per share.
• The transaction was non-discretionary, executed automatically to satisfy tax withholding obligations that arose from a vesting and settlement event of a restricted stock unit award.
• Following this transaction, Rabourn beneficially owns 190,312 shares of Opus Genetics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine, non-discretionary sale for tax purposes related to equity compensation, rather than an indication of management's sentiment about the company's future.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that such non-discretionary sales for tax purposes are common practice for executives receiving equity compensation and typically do not signal a change in management's outlook on the company's prospects within the biotechnology or pharmaceutical industry.

Comparison to Industry Standards

• Such tax-related sales are standard practice across industries for executives receiving equity compensation, aligning with common compensation structures in publicly traded companies. For example, executives at companies such as Pfizer or Moderna often execute similar non-discretionary sales upon RSU vesting to cover tax liabilities.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a lack of confidence by the reporting person.

Key Dates

Recommendation

This Form 4 reports a non-discretionary sale of shares by an officer to cover tax obligations arising from a restricted stock unit award. Such transactions are routine and do not reflect a change in the officer's investment sentiment or the company's fundamentals. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Opus Genetics, IRD, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation